NOXXON Announces Data Safety Monitoring Board Validates NOX-A12 Highest Dose in Phase 1/2 Brain Cancer Trial

NOXXON Pharma, Inc. announced that an independent Data Safety Monitoring Board has confirmed that the highest dose of NOX-A12 in combination with radiotherapy in the ongoing Phase I/II study in patients with brain cancer is safe and that the trial should continue as planned.